ArticleInflammopharmacology2025
Alphonsea elliptica (Hook.f. and Thomson) methanol leaves extract obliterates inflammatory processes in LPS-induced human plasma.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alcalase-hydrolyzed casein peptides after simulated gastrointestinal digestion alleviate high-fat diet-induced metabolic dysfunction in mice.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In our previous findings, the methanol extract of A. elliptica (MEL) exhibited platelet-activating factor inhibition, indicating possible anti-inflammatory properties. Despite its ethnopharmacological significance, no studies have thoroughly investigated its anti-inflammatory potential. Based on our preliminary findings, we hypothesised that MEL might exert anti-inflammatory effects by modulating key inflammatory mediators, such as prostaglandin E2 (PGE2), cyclooxygenase-2 (COX-2), and pro-inflammatory cytokines (IL-1β and IL-6). The cytotoxicity of MEL was assessed on peripheral blood mononuclear cells (PBMCs) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. In vitro, anti-inflammatory activity was investigated in lipopolysaccharide (LPS)-induced human plasma through an enzyme-linked immunosorbent assay (ELISA) and a radioimmunoassay. In addition, the phytochemical profile of MEL was characterised using LC-ESI-MS/MS spectrometry. The extract demonstrated no cytotoxic effects at 20 μg/mL concentrations. MEL exhibited significant anti-inflammatory activity, with notable inhibition of PGE2 (76.18%) and COX-2 (80.12%), as well as pronounced reductions in IL-1β and IL-6 levels, corresponding to 11.6-fold and ninefold decreases at 10 μg/mL, respectively. Concentration-dependent effects were observed, with IC₅₀ values of 4.09, 5.81, 2.12, and 1.97 μg/mL for PGE2, COX-2, IL-1β, and IL-6, respectively. LC-ESI-MS/MS analysis revealed the presence of 30 bioactive compounds, including Gramine, Eruberin B, and Grossamide, which likely contributed to the extract's anti-inflammatory effects. In conclusion, MEL abrogated LPS-induced inflammatory responses in human plasma at non-cytotoxic concentrations, demonstrating its potential as a natural anti-inflammatory agent. Furthermore, this study is the first to report the phytochemical composition of A. elliptica leaves, providing insights into its bioactive constituents and therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.